Back to News
Market Impact: 0.3

2 Actually Profitable Pot Stocks To Buy Before Trump's Cannabis Rescheduling

IIPRNFLXNVDANDAQ
Regulation & LegislationTax & TariffsCorporate EarningsCompany FundamentalsCapital Returns (Dividends / Buybacks)Housing & Real EstateInvestor Sentiment & PositioningConsumer Demand & Retail
2 Actually Profitable Pot Stocks To Buy Before Trump's Cannabis Rescheduling

A pending federal rescheduling directive (Dec. 18 Executive Order instructing rescheduling from Schedule I to III) could materially improve cannabis profitability by removing IRC 280E, but implementation is uncertain. Green Thumb Industries reported Q3 revenue of $291 million (+1.6% YoY) and EPS of $0.10 versus $0.04 a year earlier, with retail sales down 1% and prepackaged goods up 8%; the company operates 108 RISE dispensaries across 14 states. NewLake Capital Partners, a cannabis-focused REIT, reported Q3 revenue of $12.6 million (+0.3% YoY), AFFO per share $0.52 (+2% YoY), an 11.47% quarterly dividend yield and an AFFO payout ratio of 82%; it owns 34 properties across 12 states, carries $8 million of debt and >$24 million cash but has 24.1% exposure to Curaleaf. Investors should weigh downside execution and concentration risks against potentially significant upside from regulatory change and strong REIT cash yields.

Analysis

Market structure: Rescheduling momentum (Schedule 1→3) shifts cash-flow upside toward operators with scale (GTBIF) and landlords with long, triple-net leases (NLCP). Winners: large profitable operators (GTBIF), cannabis REITs with low leverage and sticky cash rents (NLCP); losers: highly-levered operators and single-tenant landlords with concentrated tenant risk (e.g., heavy CURLF exposure). Interest-rate sensitive REIT spreads should compress on visible margin uplift, tightening IG and high-yield spreads by a few 10s of bps if federal tax relief (280E repeal) materializes. Risk assessment: Tail risks include regulatory rollback or multi-year DOJ/DEA delay (binary; >50% value hit for leveraged operator equities), tenant bankruptcies (Curaleaf default >20% value shock to NLCP), and slower-than-expected state rollouts. Immediate (days): volatility around regulatory headlines; short-term (weeks–months): repricing on DEA/AG milestones and state adult-use launches; long-term (quarters–years): permanent margin expansion if 280E is removed. Hidden dependency: NLCP's dividend sustainability depends on tenant credit (monitor CURLF performance and AFFO >0.45/share). Trade implications: Establish a modest tactical long in NLCP (2–4% portfolio) to capture an ~11% yield with covered-call overlays; pair this long NLCP vs short IIPR (dollar-neutral) to exploit relative AFFO payout and leverage differences. For GTBIF, use long-dated call spreads (12–18 month LEAP debit spread sized 0.5–1% portfolio) to express asymmetric regulatory upside while limiting capital at risk. Reduce broad cannabis beta and rotate 1–3% into state-rollout-exposed consumer CPG suppliers if margin proof arrives. Contrarian angles: Consensus understates landlord credit risk — an NLCP dividend is attractive but overstated if Curaleaf weakens; price-in a 15–25% downside scenario for NLCP if Curaleaf defaults. Reaction is underdone on optionality: GTBIF’s profitability makes it a structural winner if 280E repeal occurs, so options markets may be mispriced for long-dated regulatory upside. Historical parallel: alcohol re-regulation events show multi-year rerating, but only after sustained legal clarity — do not treat headlines as immediate valuation certainties.